Sionna Therapeutics, Inc.

Contributing Author

Recent Articles by Sionna Therapeutics, Inc.

Nov-24	Sionna Therapeutics to Participate in Upcoming December Investor Conferences SION GlobeNewswire
Nov-05	Sionna Therapeutics Reports Third Quarter 2025 Financial Results SION GlobeNewswire
Nov-04	Sionna Therapeutics to Participate in Upcoming November Investor Conferences SION GlobeNewswire
Oct-24	Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference SION GlobeNewswire
Oct-21	Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis SION GlobeNewswire
Oct-01	Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference SION GlobeNewswire
Sep-08	Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer SION GlobeNewswire
Aug-27	Sionna Therapeutics to Participate in Upcoming September Investor Conferences SION GlobeNewswire
Aug-25	Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis SION GlobeNewswire
Aug-11	Sionna Therapeutics Reports Second Quarter 2025 Financial Results SION GlobeNewswire
Jun-06	Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model SION GlobeNewswire
Jun-04	Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis SION GlobeNewswire
Jun-03	Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference SION GlobeNewswire
May-22	Sionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis Conference SION GlobeNewswire
May-12	Sionna Therapeutics Reports First Quarter 2025 Financial Results SION GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.